This inventor holds 4 USPTO granted patents. Top assignees: Tranxenogen, Inc., Genzyme Transgenics Corporation, Gtc Biotherapeutics, Inc.. Active years: 2003-2011.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 3 
1 out of 12 
1 out of 11 Years Active: 2003-2011
Title: The Innovations of Paul DiTullio: A Pioneer in Biotechnological Advancements
Introduction: Paul DiTullio, an inventive spirit hailing from Northboro, MA, has made significant contributions to the field of biotechnology with a focus on transgenic processes and anticancer therapies. Throughout his career, he has been awarded four patents, showcasing his dedication to innovation in medical science.
Latest Patents: Among his noteworthy inventions is the development of transgenically produced antithrombin III (tgATIII). This invention pertains to the human Antithrombin III produced through a transgenic method that results in a unique monosaccharide composition. This composition includes N-acetylgalactosamine (GalNAc), fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. It has been established that tgATIII offers an increased clearance rate compared to plasma-derived ATIII (phATIII). Another of DiTullio's significant contributions is the creation of anticancer peptide compositions, which provide innovative methods for inhibiting angiogenesis related to tumors and consequently reducing tumor growth.
Career Highlights: Paul DiTullio's career spans notable positions at various companies, including Tranxenogen, Inc. and Genzyme Transgenics Corporation. His work has not only led to substantial scientific developments but has also advanced the understanding of therapeutic mechanisms in disease treatment.
Collaborations: Throughout his journey, DiTullio collaborated with esteemed colleagues, including Harry M. Meade and Li-How Chen, whose combined expertise has significantly contributed to his research and innovations in the field.
Conclusion: Paul DiTullio stands out as a prominent inventor in the biotechnology domain, with a remarkable portfolio of patents that reflect his commitment to enhancing medical science. His groundbreaking inventions in transgenic processes and cancer therapies have the potential to impact numerous lives, underscoring the importance of innovation in modern healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile